Nord/LB Reiterates €98.00 Price Target for Merck KGaA (MRK)

Nord/LB set a €98.00 ($116.67) price target on Merck KGaA (FRA:MRK) in a report published on Friday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other brokerages also recently issued reports on MRK. Kepler Capital Markets set a €115.00 ($136.90) price objective on Merck KGaA and gave the company a buy rating in a research note on Monday, November 6th. Warburg Research set a €115.00 ($136.90) price objective on Merck KGaA and gave the company a buy rating in a research note on Thursday, November 9th. Independent Research set a €103.00 ($122.62) price objective on Merck KGaA and gave the company a neutral rating in a research note on Thursday, November 9th. Berenberg Bank set a €116.00 ($138.10) price objective on Merck KGaA and gave the company a buy rating in a research note on Thursday, November 9th. Finally, Commerzbank set a €103.00 ($122.62) price objective on Merck KGaA and gave the company a neutral rating in a research note on Thursday, November 9th. Twelve analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of €107.81 ($128.34).

Merck KGaA (FRA:MRK) opened at €88.98 ($105.93) on Friday. Merck KGaA has a 1 year low of €87.33 ($103.96) and a 1 year high of €115.00 ($136.90).

TRADEMARK VIOLATION NOTICE: This piece of content was published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://weekherald.com/2017/12/11/nordlb-reiterates-98-00-price-target-for-merck-kgaa-mrk.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply